Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
0.650
+0.020 (3.17%)
Mar 6, 2026, 12:42 PM EST
-73.47%
Market Cap 36.27M
Revenue (ttm) 154.67K
Net Income (ttm) -14.26M
Shares Out 57.58M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,000
Average Volume 23,614
Open 0.650
Previous Close 0.630
Day's Range 0.650 - 0.650
52-Week Range 0.610 - 2.460
Beta n/a
RSI 32.37
Earnings Date Mar 17, 2026

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Country Canada
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.